

# Archived Document

This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of June 2023. Because of its value to the laboratory community, it is being retained in CLSI's library.



August 2013

---

## MM07-A2

# Fluorescence *In Situ* Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition

**NOTE:** CLSI document MM07-A2 does not cover some specific applications of fluorescence *in situ* hybridization (FISH) for oncology or newer technologies for automated reading and morphology-FISH overlays.

This document addresses fluorescence *in situ* hybridization methods for medical genetic determinations, identification of chromosomal abnormalities, and gene amplification. Recommendations for probe and assay development, manufacture, qualification, verification, and validation; instrument requirements; quality assurance; and evaluation of results are also included.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## **Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## **Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## **Appeals Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## **Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

ISBN 1-56238-885-1 (Print)  
ISBN 1-56238-886-X (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

MM07-A2  
Vol. 33 No. 10  
Replaces MM07-A  
Vol. 24 No. 5

---

## Fluorescence *In Situ* Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition

Volume 33 Number 10

James T. Mascarello, PhD  
Linda D. Cooley, MD, MBA, FACMG, FCAP  
Patricia K. Dowling, PhD, FACMG  
Marileila Varella Garcia, PhD  
Susan S. Jewell, PhD  
Reena Philip, PhD  
P. Nagesh Rao, PhD, FACMG  
Elizabeth Sheppard, MBA, HT(ASCP)  
Sarah T. South, PhD, FACMG  
Karen Tsuchiya, MD  
Anne Wiktor, MT, CG(ASCP)<sup>CM</sup>  
Daynna J. Wolff, PhD, FACMG

### Abstract

Clinical and Laboratory Standards Institute document MM07-A2—*Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition* provides information to ensure appropriate and reliable use of the FISH technology. FISH may be used to detect cytogenetic aberrations that are not readily evident by standard cytogenetic banding analyses. FISH technology allows for rapid identification of deletions, duplications, amplifications, and structural abnormalities of specific genes, loci, or chromosomal DNA/RNA sequences. The regions assessed by FISH are typically larger than those studied with PCR, yet smaller than those visualized microscopically with standard cytogenetics. FISH studies have become routine in medical laboratories.

Clinical and Laboratory Standards Institute (CLSI). *Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition*. CLSI document MM07-A2 (ISBN 1-56238-885-1 [Print]; ISBN 1-56238-886-X [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2013.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2013 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition*. CLSI document MM07-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.

### **Previous Editions:**

October 2001, January 2004

### **Reaffirmed:**

June 2018

### **Archived:**

June 2023

**NOTE:** CLSI document MM07-A2 does not cover some specific applications of fluorescence *in situ* hybridization (FISH) for oncology or newer technologies for automated reading and morphology-FISH overlays.

ISBN 1-56238-885-1 (Print)  
ISBN 1-56238-886-X (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

## Committee Membership

### Consensus Committee on Molecular Methods

**Frederick S. Nolte, PhD,**  
**D(ABMM), F(AAM)**  
**Chairholder**  
**Medical University Hospital**  
**Authority**  
**Charleston, South Carolina, USA**

**Barbara Zehnbauer, PhD,**  
**FACMG**  
**Vice-Chairholder**  
**Centers for Disease Control and**  
**Prevention**  
**Atlanta, Georgia, USA**

Helen Fernandes, PhD  
 UMDNJ – University Hospital  
 Newark, New Jersey, USA

Tina M. Hambuch, PhD  
 Illumina, Inc.  
 San Diego, California, USA

Charles E. Hill, MD, PhD  
 Emory University Hospital  
 Atlanta, Georgia, USA

Penny Keller, MT(ASCP)  
 Centers for Medicare & Medicaid  
 Services  
 Baltimore, Maryland, USA

Thomas J. Lenk, PhD  
 Celera Diagnostics  
 Alameda, California, USA

Yi-Wei Tang, MD, PhD,  
 D(ABMM)  
 Memorial Sloan Kettering Cancer  
 Center  
 New York, New York, USA

Zivana Tezak-Fragale, PhD  
 FDA Center for Devices and  
 Radiological Health  
 Silver Spring, Maryland, USA

Emily S. Winn-Deen, PhD  
 Rx Dx Advisors, Inc.  
 San Diego, California, USA

### Document Development Committee on Fluorescence *In Situ* Hybridization Methods for Medical Genetics

**James T. Mascarello, PhD**  
**Chairholder**  
**Integrated Genetics**  
**Santa Fe, New Mexico, USA**

Linda D. Cooley, MD, MBA,  
 FACMG, FCAP  
 Children's Mercy Hospital  
 Kansas City, Missouri, USA

Patricia K. Dowling, PhD, FACMG  
 Quest Diagnostics Incorporated  
 Teterboro, New Jersey, USA

Susan S. Jewell, PhD  
 Abbott Molecular Inc.  
 Des Plaines, Illinois, USA

Reena Philip, PhD  
 FDA Center for Devices and  
 Radiological Health  
 Silver Spring, Maryland, USA

Karen Tsuchiya, MD  
 Seattle Children's Hospital  
 Seattle, Washington, USA

Anne Wiktor, MT, CG(ASCP)<sup>CM</sup>  
 Mayo Clinic  
 Rochester, Minnesota, USA

Dayna J. Wolff, PhD, FACMG  
 Medical University Hospital  
 Authority  
 Charleston, South Carolina, USA

#### Staff

Clinical and Laboratory Standards  
 Institute  
 Wayne, Pennsylvania, USA

Luann Ochs, MS  
*Senior Vice President – Operations*

Tracy A. Dooley, MLT(ASCP)  
*Staff Liaison*

Marcy Hackenbrack, MCM,  
 M(ASCP)  
*Project Manager*

Megan L. Tertel, MA  
*Editor*

### Acknowledgment

CLSI and the Consensus Committee on Molecular Methods gratefully acknowledge the following individuals for their help in preparing the second edition of this document:

Marileila Varella Garcia, PhD  
 University of Colorado  
 Aurora, Colorado, USA

P. Nagesh Rao, PhD, FACMG  
 UCLA School of Medicine, Pathology and Laboratory Medicine  
 Los Angeles, California, USA

Elizabeth Sheppard, MBA, HT(ASCP)  
Ventana Medical Systems, Inc.  
Tucson, Arizona, USA

Sarah T. South, PhD, FACMG  
ARUP Laboratories, University of Utah  
Salt Lake City, Utah, USA

**Acknowledgment**

CLSI and the Consensus Committee on Molecular Methods gratefully acknowledge the following individuals as special reviewers:

Estelle Russek-Cohen, PhD  
FDA Center for Biologics Evaluation and Research  
Rockville, Maryland, USA

Raymond Tubbs, DO  
Cleveland Clinic  
Cleveland, Ohio, USA

## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
3 Standard Precautions.....	2
4 Terminology.....	2
4.1 A Note on Terminology .....	2
4.2 Definitions .....	2
4.3 Abbreviations and Acronyms .....	4
5 Background.....	5
6 Clinical Applications of FISH .....	5
6.1 Types of Probes .....	6
6.2 Metaphase Applications.....	6
6.3 Interphase Applications .....	7
7 Production of New FISH Probes.....	10
8 Development, Validation, and Verification of FISH Tests.....	10
8.1 What Is the Measurand (Analyte)? .....	11
8.2 What Is the Test? .....	12
8.3 Test Sensitivity and Specificity .....	12
8.4 Introducing a New FISH Test Into the Laboratory .....	15
8.5 Test Reproducibility .....	23
8.6 Controls.....	24
9 Analytical Processes .....	24
9.1 Use of Controls .....	24
9.2 Metaphase Analysis .....	25
9.3 Interphase Analysis.....	25
9.4 Scoring for Chromosome/Target Enumeration.....	27
9.5 Scoring for Fusion and Break-Apart Probe Sets.....	27
9.6 Paraffin-Embedded Tissue Sections .....	27
9.7 Paraffin-Embedded Tissue, Extracted Nuclei.....	28
9.8 Use of FISH for Confirmation of Genomic Microarray Results and Follow-up Family Studies .....	28
10 Reporting .....	28
10.1 Report Contents .....	28
10.2 Disclaimers to Consider With Report .....	29
10.3 Records .....	30
11 Quality Management.....	30

**Contents (Continued)**

11.1 Personnel.....30

11.2 Documents and Records .....31

11.3 Quality Control .....31

11.4 Quality Assurance.....32

12 Equipment Used in FISH Testing .....33

12.1 Water Baths and Slide Warmers .....33

12.2 Slides.....33

12.3 Automated FISH Slide Processing.....34

12.4 Thermometers and Pipettes.....34

12.5 Ambient Lighting for Microscopy .....35

12.6 Microscopes .....35

12.7 Analytical Automation.....37

References.....38

The Quality Management System Approach .....40

Related CLSI Reference Materials .....41

## Foreword

The CLSI Document Development Committee on Fluorescence *In Situ* Hybridization Methods for Medical Genetics was formed to address the need for a guideline on FISH assay development, verification, and clinical validation. This guideline will be useful to clinical laboratories that develop and/or use FISH assays and to agencies that regulate those laboratories. To a lesser extent it may be of value to manufacturers of FISH probes and other reagents used in FISH testing. This guideline expands and revises the previous edition of MM07.

## Summary of Major Changes in This Document

- The entire document has been reorganized and updated. Wherever possible, examples have been added to illustrate characteristics of FISH tests.
- FISH technology is being used in settings other than genetic laboratories. Thus, the target audience has been expanded to include all clinical laboratories.
- Although manufacturers of reagents used for FISH testing may find value in knowing the standards applicable to testing laboratories, this guideline no longer includes manufacturing standards.
- Because FISH testing is used heavily in oncology, a greater emphasis has been placed on oncology-related FISH issues in this edition of the guideline.
- Discussion of nonfluorescent detection methods has been added.
- Background information on testing strategies and how FISH testing is used in a clinical setting has been expanded.
- The nature of “measurands (analytes)” detected by FISH testing is discussed in detail and related to other aspects of cytogenetic testing. Also added is a discussion of how FISH testing’s ability to simultaneously detect a potentially large number of analytes impacts test development and test performance.
- Because the measurand (analyte) is sometimes a change in relative position of FISH targets, the sensitivity and specificity of the FISH probe has been distinguished from analytical sensitivity and analytical specificity.
- Statistical methods and a discussion of their limitations for establishing normal cutoff values used to detect mosaicism or the acquired abnormalities associated with neoplasia has been added.
- Discussion of issues pertaining to formalin-fixed, paraffin-embedded samples; samples with selected or enriched cell populations, and samples used for FISH testing in support of microarray analysis has been added.

Note that the methods and QC approaches described in this guideline are based on current clinical applications of FISH testing and that, as new technical methods and clinical applications evolve, other QC methods may be appropriate.

## Key Words

Chromosome, cytogenetics, FISH, fluorescence *in situ* hybridization



# Fluorescence *In Situ* Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition

## 1 Scope

This document addresses fluorescence *in situ* hybridization methods for medical genetic determinations, identification of chromosomal abnormalities, and gene amplification. Recommendations for probe and assay development, manufacture, qualification, verification, and validation; instrument requirements; QA; and evaluation of results are also included. The guideline is intended to facilitate the reproducible production of FISH assays and the interlaboratory comparison of results and diagnostic interpretations, as well as to ensure accuracy in diagnosis.

This document is intended for use by laboratories that develop tests based on commercially manufactured and laboratory-developed FISH probes. Unlike the previous edition, this revised guideline does not specifically address issues associated with the manufacturing of FISH probes or *in vitro* diagnostic (IVD) devices based on FISH technology. Nevertheless, manufacturers may find value in the principles of FISH testing presented in this guideline and in better understanding how their products will be used by laboratories.

## 2 Introduction

This guideline primarily addresses “fluorescence” *in situ* hybridization because fluorescence is currently the most widely used method for demonstrating the location of the hybridized probe. Chromogenic *in situ* hybridization (CISH), silver precipitation *in situ* hybridization (SISH), and other nonfluorescent approaches are also in use. Although each of these approaches has its own technical strengths and limitations, the principles of test development and performance are expected to be similar to those described here for fluorescence.

FISH allows geneticists to detect the location of genomic targets (eg, genes, anonymous sequences, and repeat sequences) in a variety of situations. FISH makes use of “probes”: DNA strands with a sequence complementary to a genomic target of interest. Although FISH was originally used primarily for genomic mapping purposes, it has rapidly become an indispensable method for clinical cytogenetic applications. In metaphase cells, FISH can be used to characterize abnormalities detected by conventional chromosome analysis and can also be used to detect abnormalities such as microdeletions and cryptic rearrangements that are not readily detected by conventional chromosome analysis. In interphase cells, FISH can be used to count (enumerate) the number of specific targets in a nucleus and assess changes in the relative position of specific targets. Moreover, the ability to use interphase cells extends the capabilities of cytogenetics by making it possible to include large numbers of cells in FISH analysis and to evaluate tissues with low (or no) mitotic activity.

Presently, venues for probe manufacturing range from contract services to tightly controlled, heavily regulated manufacturing of probes such as those included in US Food and Drug Administration (FDA)–approved test kits. Thus, manufacturing is sufficiently complex to justify one or more guidelines unto itself. Probe manufacturers are encouraged to investigate the regulatory requirements pertinent to the locations in which probes are manufactured and/or sold, and may find value in other CLSI guidelines relating to manufacturing and product stability of reagents intended for laboratory testing (see CLSI document EP25).<sup>1</sup>